{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T14:26:56Z","timestamp":1777386416373,"version":"3.51.4"},"reference-count":52,"publisher":"SAGE Publications","issue":"2","license":[{"start":{"date-parts":[[2018,12,27]],"date-time":"2018-12-27T00:00:00Z","timestamp":1545868800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Am J Rhinol\ufffdAllergy"],"published-print":{"date-parts":[[2019,3]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Chronic rhinosinusitis with nasal polyposis is a complex inflammatory disorder, which is often recalcitrant to medical and surgical management. Recently, biologic agents have been studied as an adjunct treatment for this patient population.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>The purpose of this study is to examine the role of biologic agents for chronic rhinosinusitis patients by reviewing literature and clinical trials.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A comprehensive review of literature and clinical trials\u2014both recently completed and ongoing\u2014was undertaken to examine up-to-date evidence of current biologic therapy and its role in chronic rhinosinusitis patients\u2014including anti-IgE, anti-IL-4, anti-IL-5, anti-IL-13, and GATA-3 DNAzyme.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Specific biologic agents discussed include omalizumab, reslizumab, mepolizumab, benralizumab, dupilumab, and Hgd40\/SB010. Risks, side effects, and administration information are also reviewed. An algorithm for the use of biologics in patients with chronic rhinosinusitis with nasal polyposis is proposed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>These treatments have promising results and may prove to be an important adjunct for patients with recalcitrant sinus disease.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/1945892418814768","type":"journal-article","created":{"date-parts":[[2018,12,27]],"date-time":"2018-12-27T05:00:37Z","timestamp":1545886837000},"page":"203-211","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":52,"title":["Biologic Agents for the Treatment of Chronic Rhinosinusitis With Nasal Polyps"],"prefix":"10.1177","volume":"33","author":[{"given":"Alison G.","family":"Kartush","sequence":"first","affiliation":[{"name":"Department of Otolaryngology, Head and Neck Surgery, Loyola University Medical Center, Maywood, Illinois"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jane K.","family":"Schumacher","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine. Affiliate clinician: Loyola University Medical Center, Maywood, Illinois"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rachna","family":"Shah","sequence":"additional","affiliation":[{"name":"Department of Otolaryngology, Head and Neck Surgery, Loyola University Medical Center, Maywood, Illinois"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Monica O.","family":"Patadia","sequence":"additional","affiliation":[{"name":"Department of Otolaryngology, Head and Neck Surgery, Loyola University Medical Center, Maywood, Illinois"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2018,12,27]]},"reference":[{"key":"bibr1-1945892418814768","doi-asserted-by":"publisher","DOI":"10.1016\/j.anai.2016.10.028"},{"key":"bibr2-1945892418814768","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2009.05.017"},{"key":"bibr3-1945892418814768","unstructured":"Clinicaltrials.gov [Internet]. Safety, efficacy, PK, and PD characteristics of orally inhaled SB010 in male patients with mild asthma (multiple dose). https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01743768. Published 2017."},{"key":"bibr4-1945892418814768","doi-asserted-by":"publisher","DOI":"10.1177\/0003489417731782"},{"key":"bibr5-1945892418814768","first-page":"CD011995","volume":"4","author":"Chong LY","year":"2016","journal-title":"Cochrane Database Syst Rev"},{"key":"bibr6-1945892418814768","first-page":"CD011996","volume":"4","author":"Chong LY","year":"2016","journal-title":"Cochrane Database Syst Rev"},{"key":"bibr7-1945892418814768","doi-asserted-by":"publisher","DOI":"10.1097\/01.mlg.0000205218.37514.0f"},{"key":"bibr8-1945892418814768","first-page":"CD011994","volume":"4","author":"Head K","year":"2016","journal-title":"Cochrane Database Syst Rev"},{"key":"bibr9-1945892418814768","doi-asserted-by":"publisher","DOI":"10.1016\/j.otohns.2008.07.010"},{"key":"bibr10-1945892418814768","doi-asserted-by":"publisher","DOI":"10.1002\/alr.21780"},{"key":"bibr11-1945892418814768","doi-asserted-by":"publisher","DOI":"10.2500\/ajra.2009.23.3334"},{"key":"bibr12-1945892418814768","unstructured":"Novartis.ca [Internet]. Product Monograph: Pr XOLAIR\u00ae (omalizumab). https:\/\/www.novartis.ca\/sites\/www.novartis.ca\/files\/xolair_scrip_e.pdf. Published 2017."},{"key":"bibr13-1945892418814768","doi-asserted-by":"publisher","DOI":"10.1186\/s13223-017-0219-4"},{"key":"bibr14-1945892418814768","doi-asserted-by":"publisher","DOI":"10.1111\/cea.12287"},{"key":"bibr15-1945892418814768","doi-asserted-by":"publisher","DOI":"10.1164\/ajrccm.164.supplement_1.2103025"},{"key":"bibr16-1945892418814768","doi-asserted-by":"publisher","DOI":"10.2500\/aap.2012.33.3599"},{"key":"bibr17-1945892418814768","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2014.02.007"},{"key":"bibr18-1945892418814768","unstructured":"Fda.gov [Internet]. FDA Drug Safety Communication: FDA approves label changes for asthma drug Xolair (omalizumab), including describing slightly higher risk of heart and brain adverse events. https:\/\/www.fda.gov\/Drugs\/DrugSafety\/ucm414911.html. Published 2017."},{"key":"bibr19-1945892418814768","unstructured":"Fda.gov [Internet]. Xolair Label FDA. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2007\/103976s5102lbl.pdf. Published 2017."},{"key":"bibr20-1945892418814768","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2012.07.047"},{"key":"bibr21-1945892418814768","doi-asserted-by":"publisher","DOI":"10.4193\/Rhin17.156"},{"key":"bibr22-1945892418814768","doi-asserted-by":"publisher","DOI":"10.4193\/Rhino09.144"},{"key":"bibr23-1945892418814768","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjoto.2015.05.008"},{"key":"bibr24-1945892418814768","doi-asserted-by":"publisher","DOI":"10.1016\/j.aller.2012.02.005"},{"key":"bibr25-1945892418814768","first-page":"448","volume":"20","author":"Bobolea I","year":"2010","journal-title":"J Investig Allergol Clin Immunol"},{"key":"bibr26-1945892418814768","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2016.06.032"},{"key":"bibr27-1945892418814768","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2007.01.041"},{"key":"bibr28-1945892418814768","doi-asserted-by":"publisher","DOI":"10.1016\/S0091-6749(97)80019-X"},{"key":"bibr29-1945892418814768","unstructured":"Reslizumab. https:\/\/www.accessdata.fda.gov"},{"key":"bibr30-1945892418814768","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2011.07.056"},{"key":"bibr31-1945892418814768","unstructured":"Fda.gov [Internet]. Cinqair (reslizumab) Label FDA. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2016\/761033lbl.pdf. Published 2017."},{"key":"bibr32-1945892418814768","unstructured":"Omalizumab.\n                      FDA\n                      . www.fda.gov"},{"key":"bibr33-1945892418814768","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMx150017"},{"key":"bibr34-1945892418814768","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2006.05.031"},{"key":"bibr35-1945892418814768","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2017.05.044"},{"key":"bibr36-1945892418814768","doi-asserted-by":"publisher","DOI":"10.1517\/14712598.2012.642359"},{"key":"bibr37-1945892418814768","unstructured":"Fda.gov [Internet]. Nucala (mepolizumab) Label FDA. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2015\/125526Orig1s000Lbl.pdf. Published 2017."},{"key":"bibr38-1945892418814768","unstructured":"Astrazeneca.com [Internet]. Fasenra (benralizumab) receives US FDA approval for severe eosinophilic asthma. https:\/\/www.astrazeneca.com\/media-centre\/press-releases\/2017\/fasenra-benralizumab-receives-us-fda-approval-for-severe-uncontrolled-eosinophilic-asthma-14112017.html. Published 2017."},{"key":"bibr39-1945892418814768","doi-asserted-by":"publisher","DOI":"10.12688\/f1000research.13170.1"},{"key":"bibr40-1945892418814768","unstructured":"Clinicaltrials.gov [Internet]. Study of benralizumab (KHK4563) in patients with eosinophilic chronic rhinosinusitis. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02772419. Published 2017."},{"key":"bibr41-1945892418814768","unstructured":"Dupilumab.\n                      FDA\n                      . www.fda.gov"},{"key":"bibr42-1945892418814768","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2015.19330"},{"key":"bibr43-1945892418814768","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2015.10.010"},{"key":"bibr44-1945892418814768","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1411776"},{"key":"bibr45-1945892418814768","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2017.10.006"},{"key":"bibr46-1945892418814768","doi-asserted-by":"publisher","DOI":"10.1513\/AnnalsATS.201609-720OC"},{"key":"bibr47-1945892418814768","doi-asserted-by":"publisher","DOI":"10.1016\/j.anai.2014.06.014"},{"key":"bibr48-1945892418814768","first-page":"1","author":"Dedaj R","year":"2018","journal-title":"J Asthma"},{"key":"bibr49-1945892418814768","doi-asserted-by":"publisher","DOI":"10.1016\/j.anai.2017.08.272"},{"key":"bibr50-1945892418814768","doi-asserted-by":"publisher","DOI":"10.1111\/all.12914"},{"issue":"5","key":"bibr51-1945892418814768","first-page":"1566","volume":"137","author":"Buchheit KM","year":"2016","journal-title":"e5"},{"key":"bibr52-1945892418814768","doi-asserted-by":"publisher","DOI":"10.1007\/s13555-017-0201-6"}],"container-title":["American Journal of Rhinology &amp; Allergy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1945892418814768","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/1945892418814768","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1945892418814768","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T09:36:03Z","timestamp":1777368963000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/1945892418814768"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,12,27]]},"references-count":52,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2019,3]]}},"alternative-id":["10.1177\/1945892418814768"],"URL":"https:\/\/doi.org\/10.1177\/1945892418814768","relation":{},"ISSN":["1945-8924","1945-8932"],"issn-type":[{"value":"1945-8924","type":"print"},{"value":"1945-8932","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,12,27]]}}}